Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Resverlogix Corp T.RVX

Alternate Symbol(s):  RVXCF

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.


TSX:RVX - Post by User

Bullboard Posts
Comment by barsaxon Nov 18, 2019 3:10pm
169 Views
Post# 30366230

RE:RE:RE:RE:LOL, that was impressive

RE:RE:RE:RE:LOL, that was impressiveOlivier,

First, a little background - set-up.  There are several institutional owners of RVX that collectively own about 70% of all fully diluted outstanding shares...that may include RVX insiders, I'm not sure, but doesn't change my thinking.  For the purposes of my thesis I will use 230 million fully diluted shares....again I know that is not 100% accurate, but close enough for now.  So the large owners already have 160 million shares.  Meaning, they are 70 million shares away from complete 100% ownership.  If the share price fell to $1 (it could) the large owners would only have to pony up another $70 million dollars to go after all of the remaining shares.  Now there are problems with this thinking.  I believe the large owners would have to collectively, or individually put forth a tender offer to the remaining shareholders to take it private.  But the point is, if it gets too cheap, the large players will take it private.  This will allow them to protect their investment in the stock, and they have the financial wherewithall to withstand the volatility, the extra cash for needed funding and the patience to see this through to commercialization.  In essence, they are driving the bus, not you or me.  Folks like you or me can get faked out by the daily volatility.  RVX has an oustanding product that is very close to the finish line. Focus on that
Bullboard Posts